News | March 19, 2024
Dr. Reddy's Laboratories launches Versavo in the UK
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
Laurus Labs has announced that the USFDA completed inspection of the formulations manufacturing facility Unit-2, APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
The observations primarily relate to the need for improving strategies for microbial control, enhancing quality oversight, augmenting the use of software applications & computerized tools
Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
Subscribe To Our Newsletter & Stay Updated
